AbCellera Biologics (8QQ) Stock Forecast & Price Target

Compare

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

8QQ Analyst Ratings

Strong Buy

4 Buy

0 Hold

0 Sell

Based on 4 analysts giving stock ratings to

AbCellera

Biologics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

8QQ Stock 12 Month Forecast

Average Price Target

€6.11

▲(95.34% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for AbCellera Biologics in the last 3 months. The average price target is €6.11 with a high forecast of €6.11 and a low forecast of €6.11. The average price target represents a 95.34% change from the last price of €3.13.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","7":"€7","1.75":"€1.75","3.5":"€3.5","5.25":"€5.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6.11415119,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€6.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.11415119,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€6.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.11415119,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€6.11</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.75,3.5,5.25,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.908,3.1546270146153845,3.401254029230769,3.6478810438461537,3.8945080584615384,4.141135073076923,4.387762087692308,4.634389102307693,4.881016116923077,5.127643131538462,5.3742701461538465,5.620897160769231,5.867524175384616,{"y":6.11415119,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.908,3.1546270146153845,3.401254029230769,3.6478810438461537,3.8945080584615384,4.141135073076923,4.387762087692308,4.634389102307693,4.881016116923077,5.127643131538462,5.3742701461538465,5.620897160769231,5.867524175384616,{"y":6.11415119,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.908,3.1546270146153845,3.401254029230769,3.6478810438461537,3.8945080584615384,4.141135073076923,4.387762087692308,4.634389102307693,4.881016116923077,5.127643131538462,5.3742701461538465,5.620897160769231,5.867524175384616,{"y":6.11415119,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.494,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.979,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.209,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.747,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.591,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.379,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.632,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 62, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.104,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 117, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.908,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 126, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€6.11

Average Price Target€6.11

Lowest Price Target€6.11

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

02/26/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Teladoc (NYSE: TDOC), AbCellera Biologics (NASDAQ: ABCL) and Cytokinetics (NASDAQ: CYTK)

Stephen Willey

Stifel Nicolaus

€6.06

Buy

93.59%

Upside

Reiterated

02/25/26

AbCellera Biologics (ABCL) Receives a Buy from Stifel Nicolaus

Evan Seigerman

BMO Capital

€6.06

Buy

93.59%

Upside

Reiterated

02/24/26

BMO Capital Remains a Buy on AbCellera Biologics (ABCL)

Brendan Smith

TD Cowen

―

Buy

―

Reiterated

02/24/26

Analysts Are Bullish on These Healthcare Stocks: Cardiff Oncology (CRDF), AbCellera Biologics (ABCL)

David Martin PhD

Bloom Burton

€7.79

Buy

148.90%

Upside

Reiterated

11/19/25

Strategic Shift and Promising Antibody Therapeutics Drive Buy Rating for AbCellera Biologics

Faisal Khurshid

Jefferies

€3.46

Hold

10.62%

Upside

Downgraded

11/07/25

AbCellera downgraded to Market Perform from Outperform at LeerinkAbCellera downgraded to Market Perform from Outperform at Leerink

Robert Wasserman

Benchmark Co.

―

Hold

―

Reiterated

08/13/25

Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (NASDAQ: OKUR) and AbCellera Biologics (NASDAQ: ABCL)

Allison Bratzel

Piper Sandler

€14.72

Buy

370.14%

Upside

Reiterated

07/28/25

AbCellera Biologics (ABCL) Gets a Buy from Piper Sandler

Scott Schoenhaus

KeyBanc

€3.46→€4.33

Buy

38.28%

Upside

Reiterated

04/16/25

KeyBanc Remains a Buy on AbCellera Biologics (ABCL)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

02/26/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Teladoc (NYSE: TDOC), AbCellera Biologics (NASDAQ: ABCL) and Cytokinetics (NASDAQ: CYTK)

Stephen Willey

Stifel Nicolaus

€6.06

Buy

93.59%

Upside

Reiterated

02/25/26

AbCellera Biologics (ABCL) Receives a Buy from Stifel Nicolaus

Evan Seigerman

BMO Capital

€6.06

Buy

93.59%

Upside

Reiterated

02/24/26

BMO Capital Remains a Buy on AbCellera Biologics (ABCL)

Brendan Smith

TD Cowen

―

Buy

―

Reiterated

02/24/26

Analysts Are Bullish on These Healthcare Stocks: Cardiff Oncology (CRDF), AbCellera Biologics (ABCL)

David Martin PhD

Bloom Burton

€7.79

Buy

148.90%

Upside

Reiterated

11/19/25

Strategic Shift and Promising Antibody Therapeutics Drive Buy Rating for AbCellera Biologics

Faisal Khurshid

Jefferies

€3.46

Hold

10.62%

Upside

Downgraded

11/07/25

AbCellera downgraded to Market Perform from Outperform at LeerinkAbCellera downgraded to Market Perform from Outperform at Leerink

Robert Wasserman

Benchmark Co.

―

Hold

―

Reiterated

08/13/25

Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (NASDAQ: OKUR) and AbCellera Biologics (NASDAQ: ABCL)

Allison Bratzel

Piper Sandler

€14.72

Buy

370.14%

Upside

Reiterated

07/28/25

AbCellera Biologics (ABCL) Gets a Buy from Piper Sandler

Scott Schoenhaus

KeyBanc

€3.46→€4.33

Buy

38.28%

Upside

Reiterated

04/16/25

KeyBanc Remains a Buy on AbCellera Biologics (ABCL)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AbCellera Biologics

3 Months

xxx

Success Rate

4/9 ratings generated profit

Average Return

+12.72%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of +12.72% per trade.

1 Year

Brendan SmithTD Cowen

Success Rate

5/9 ratings generated profit

Average Return

+13.22%

reiterated a buy rating 21 days ago

Copying Brendan Smith's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +13.22% per trade.

2 Years

xxx

Success Rate

5/9 ratings generated profit

Average Return

+7.87%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 55.56% of your transactions generating a profit, with an average return of +7.87% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

8QQ Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

117

126

Sell

Strong Sell

total

122

131

In the current month, 8QQ has received 5 Buy Ratings, 126 Hold Ratings, and 0 Sell Ratings. 8QQ average Analyst price target in the past 3 months is 6.11.

Each month's total comprises the sum of three months' worth of ratings.

8QQ Financial Forecast

8QQ Earnings Forecast

Next quarter’s earnings estimate for 8QQ is -€0.13 with a range of -€0.17 to -€0.08. The previous quarter’s EPS was -€0.03. 8QQ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 8QQ has Performed in-line its overall industry.

8QQ Sales Forecast

Next quarter’s sales forecast for 8QQ is €4.80M with a range of €2.03M to €7.61M. The previous quarter’s sales results were €37.92M. 8QQ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 8QQ has Performed in-line its overall industry.

8QQ Stock Forecast FAQ

What is DE:8QQ’s average 12-month price target, according to analysts?

Based on analyst ratings, Abcellera Biologics, Inc.’s 12-month average price target is 6.11.

What is DE:8QQ’s upside potential, based on the analysts’ average price target?

Abcellera Biologics, Inc. has 95.34% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Abcellera Biologics, Inc. a Buy, Sell or Hold?

Abcellera Biologics, Inc. has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.

What is Abcellera Biologics, Inc.’s share price target?

The average share price target for Abcellera Biologics, Inc. is 6.11. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €6.11 ,and the lowest forecast is €6.11. The average share price target represents 95.34% Increase from the current price of €3.13.

What do analysts say about Abcellera Biologics, Inc.?

Abcellera Biologics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of Abcellera Biologics, Inc.?

To buy shares of DE:8QQ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

AbCellera Biologics (8QQ) Stock Forecast & Price Target

8QQ Analyst Ratings

8QQ Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AbCellera Biologics

8QQ Analyst Recommendation Trends

8QQ Financial Forecast

8QQ Earnings Forecast

8QQ Sales Forecast

8QQ Stock Forecast FAQ

Detailed List of Analyst Forecasts